Resistance rates (%) (95% confidence intervals) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Country | Swabs | Isolates ofS. aureus | Azithromycin | Clindamycin | Erythromycin | Oxacillin | Penicillin | Fucidic acid | Mupirocin |
Austria | 111 | 23 (20.7%) | 30.4** (21.4-39.4) | 13.0 (6.4-19.6) | 30.4** (21.4-39.4) | 0 | 73.9 (65.3-82.5) | 4.3 (0.3-8.3) | 0 |
Belgium | 101 | 30 (22.9%) | 16.7 (9.4-24) | 16.6 (9.3-23.9) | 16.6 (9.3-23.9) | 0 | 63.3 (53.9-72.7) | 0 | 0 |
Croatia | 562 | 152 (27.0%) | 5.3 (0.9-9.7) | 4.6 (0.5-8.7) | 5.3 (0.9-9.7) | 0.7 (0-2.3) | 88.2** (81.9-94.5) | 0 | 0 |
France | 309 | 94 (30.4%) | 11.7 (5.4-18.0) | 8.5 (3.0-14.0) | 10.6 (4.6-16.6) | 1.1 (0-3.1) | 79.8 (71.9-87.7) | 2.1 (0-4.9) | 0 |
Hungary | 930 | 171 (18.4%) | 16.4** (9.1-23.7) | 16.4 (9.1-23.7) | 16.4 (9.1-23.7) | 0.6 (0-2.1) | 86.0** (79.2-92.8) | 0 | 0 |
NL | 323 | 119 (36.8%) | 5.9 (1.3-10.5) | 3.4 (0-7) | 4.2 (0.3-8.1) | 0 | 73.1 (64.4-81.8) | 0.5 (0-1.9) | 0 |
Spain | 427 | 146 (34.4%) | 12.3 (5.9-18.7) | 10.3 (4.3-16.3) | 12.3 (5.9-18.7) | 0.7 (0-2.3) | 91.8* (86.4-97.2) | 0 | 3.4 (0 -7.0) |
Sweden | 345 | 104 (30.1%) | 2.9 (0-6.2) | 2.9 (0-6.2) | 2.9 (0-6.2) | 0 | 73.1* (64.4-81.8) | 2.0 (0-4.7) | 0 |
UK | No children in study sample due to ethical considerations |